Trial Profile
A Randomized, Global Study of Resolute Onyx Drug-Eluting Stent and One-Month Dual Antiplatelet Therapy
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 21 Dec 2020
Price :
$35
*
At a glance
- Drugs Zotarolimus (Primary) ; Aspirin
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Adverse reactions
- Acronyms RESOLUTE ONYX ONE-MONTH DAPT
- 21 Dec 2020 Status changed from not yet recruiting to recruiting as per results presented at the 32nd Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics
- 23 Aug 2017 New trial record
- 14 Aug 2017 According to a Medtronic media release, Stephan Windecker, M.D., of Bern University Hospital in Switzerland is the principal investigator of the study.